For the second year in a row, MDF represented the DM community in Rare Disease Week activities on Capitol Hill and at the National Institutes of Health as part of the Rare Disease Legislative Advocates conference.
FDA's Orphan Drug Program is designed to encourage pharmaceutical companies to develop drugs for rare or 'orphan' diseases that might otherwise not be appealing to industry.
On Friday, September 26, 2014, the MD-CARE Amendments were signed into law by President Obama!
Exciting news out of Washington, DC: the House of Representatives' Energy & Commerce Committee ordered the MD-CARE Act to advance to the House floor!
On June 19, the House of Representatives' Energy & Commerce Subcommittee on Health marked up the MD-CARE Act and voted to advance the bill!